Rhinomed (ASX:RNO) advises it has undertaken a AUD$2.19 million private placement to two US based sophisticated investor groups as part of its 15% placement capacity. In addition, the company has flagged its intention to hold a General Meeting to approve a capital management initiative that will seek to consolidate the company's capital and provide a sale of less than marketable share parcels facility.
Rhinomed Limited (ASX:RNO) is a Melbourne, Australia based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets.
Rhinomed (ASX:RNO) is pleased to provide an update on the expansion of its global distribution program. The company can report that Rhinomed has been added as a vendor by two major US based pharmacy wholesalers and the successful expansion of the listing of its Mute Sleep technology by Symbion in Australia.
Rhinomed (ASX:RNO) has had a strong first quarter of the financial year with positive traction across its consumer health and clinical businesses.
Rhinomed Ltd (ASX:RNO) has launched two products into global markets during the financial year: launching our new sleep quality aid, Mute(TM) into the global sleep device market and a new generation Turbine(TM) sports product in response to feedback from users.
Rhinomed Limited (ASX:RNO) is pleased to announce today that it has raised a total of A$2.5m by a way of a placement of 78,125,000 fully paid ordinary shares at A$0.032 per shares with institutional, Sophisticated, and Offshore investors (placement).
Australian respiratory technology company, Rhinomed (ASX:RNO) is pleased to announce it has entered into a landmark partnership with SleepGP, a growing network of GP practices, to raise awareness of sleep disordered breathing issues within the family medicine setting.
Rhinomed Ltd (ASX:RNO) has been building its international presence and connections amongst the international investment and pharmaceutical community this year. In March, Michael Johnson was the keynote 'Rising Star' presentation at the Master Investor Show in London.
Australian respiratory technology company Rhinomed Ltd (ASX:RNO) is pleased to advise it has increased its production line capacity at the ChinaMed production facility.
Australian respiratory technology company Rhinomed Ltd (ASX:RNO), is pleased to announce its Mute snoring and sleep technology will be available on pharmacy shelves in the United Kingdom from late October 2015.
Key highlights of the quarter included the growing demand for the company's new Turbine design and strong early demand for the Mute snoring and sleep technology. Receipts from Customers for the quarter were up $33k to $192k. Revenues from the Australian pharmacy channel will be included during the next quarter